GALAXI-1 Study - Guselkumab effective in Crohn's Disease. 309 CD pts (1/2 refractory dz) Rx w/ either PBO, or IV GUS 2
Tweet Content
GALAXI-1 Study - Guselkumab effective in Crohn's Disease. 309 CD pts (1/2 refractory dz) Rx w/ either PBO, or IV GUS 200 mg, 600 mg, or 1200 mg at weeks 0, 4, and 8; At week 12, all 3 doses had signif. clinical and endoscopic improvements vs PBO https://t.co/iGyAmCoO96
Links
Show on Archive Page
On
Display in Search Results
On
PDQ
Off